Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

UBS
Citi
Accenture
Farmers Insurance
Argus Health
AstraZeneca
Boehringer Ingelheim
Federal Trade Commission
Fish and Richardson
Chubb

Generated: August 21, 2017

DrugPatentWatch Database Preview

TECHNIVIE Drug Profile

« Back to Dashboard

What is the patent landscape for Technivie, and when can generic versions of Technivie launch?

Technivie is a drug marketed by Abbvie Inc and is included in one NDA. There are twelve patents protecting this drug.

This drug has three hundred and fifty-three patent family members in forty-seven countries.

The generic ingredient in TECHNIVIE is ombitasvir; paritaprevir; ritonavir. One supplier is listed for this compound. Additional details are available on the ombitasvir; paritaprevir; ritonavir profile page.

Summary for Tradename: TECHNIVIE

Patents:12
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Clinical Trials: see list2
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:TECHNIVIE at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie Inc
TECHNIVIE
ombitasvir; paritaprevir; ritonavir
TABLET;ORAL207931-001Jul 24, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Abbvie Inc
TECHNIVIE
ombitasvir; paritaprevir; ritonavir
TABLET;ORAL207931-001Jul 24, 2015RXYesYes► Subscribe► Subscribe ► Subscribe
Abbvie Inc
TECHNIVIE
ombitasvir; paritaprevir; ritonavir
TABLET;ORAL207931-001Jul 24, 2015RXYesYes► Subscribe► Subscribe ► Subscribe
Abbvie Inc
TECHNIVIE
ombitasvir; paritaprevir; ritonavir
TABLET;ORAL207931-001Jul 24, 2015RXYesYes► Subscribe► SubscribeY► Subscribe
Abbvie Inc
TECHNIVIE
ombitasvir; paritaprevir; ritonavir
TABLET;ORAL207931-001Jul 24, 2015RXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: TECHNIVIE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie Inc
TECHNIVIE
ombitasvir; paritaprevir; ritonavir
TABLET;ORAL207931-001Jul 24, 2015► Subscribe► Subscribe
Abbvie Inc
TECHNIVIE
ombitasvir; paritaprevir; ritonavir
TABLET;ORAL207931-001Jul 24, 2015► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: TECHNIVIE

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,023,8782-iminobiotin formulations and uses thereof► Subscribe
8,691,878Solid pharmaceutical dosage form► Subscribe
8,309,613Solid pharmaceutical dosage form► Subscribe
8,333,990Solid pharmaceutical dosage form► Subscribe
8,716,454Solid compositions► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: TECHNIVIE

Country Document Number Estimated Expiration
Taiwan201231064► Subscribe
Taiwan201238948► Subscribe
Hong Kong1171184► Subscribe
CroatiaP20140492► Subscribe
Portugal2295052► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: TECHNIVIE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0021France► SubscribePRODUCT NAME: PARITAPREVIR DANS TOUTES LES FORMES PROTEGEES PAR LE BREVET DE BASE; REGISTRATION NO/DATE: EU/1/14/982 20150119
0731Netherlands► SubscribePRODUCT NAME: OMBITASVIR OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/14/982 20150119
2015011Lithuania► SubscribePRODUCT NAME: PARITAPREVIRUM; REGISTRATION NO/DATE: EU/1/14.982 20150115
2015000039Germany► SubscribePRODUCT NAME: OMBITASVIR; REGISTRATION NO/DATE: EU/1/14/982 20150115
C0016France► SubscribePRODUCT NAME: OMBITASVIR DANS TOUTES LES FORMES PROTEGEES PAR LE BREVET DE BASE; REGISTRATION NO/DATE: EU/1/14/982 20150119
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Citi
US Army
Covington
Cantor Fitzgerald
Novartis
UBS
Medtronic
Mallinckrodt
Argus Health
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot